WeVote
Log In

Bill

Bill

HB 2740

Adopting compounding standards established by the United States pharmacopeia and allowing for exemptions from such standards.

2025-2026 Regular Session

Kansas would adopt USP compounding standards, with defined exemption processes, improving quality while allowing selective waivers.

Died in Senate Committee
#pharmacistsandpharmacy
0
WeVote Research Nonpartisan
Bill Summary · HB 2740

Summary of HB 2740 (Kansas, 2025-2026)

Purpose and intent

HB 2740 seeks to adopt compounding standards established by the United States Pharmacopeia (USP) in Kansas and provides for exemptions from those standards under certain conditions. The bill aims to align state compounding practice with USP standards, potentially enhancing quality and consistency in pharmaceutical compounding while allowing targeted exemptions where justified.

Key provisions and changes

  • Adoption of USP standards: The bill requires compounding practices in Kansas to meet standards established by the United States Pharmacopeia. This includes procedures, quality controls, documentation, and other practice requirements that USP sets for pharmacy compounding.
  • Exemptions from standards: HB 2740 creates mechanisms by which exemptions from USP standards may be granted. The bill likely outlines criteria, processes, and authorities for granting exemptions, though the exact scope (e.g., emergency use, patient-specific exceptions, or department-level discretion) would be detailed in the text.
  • Regulatory alignment: By adopting USP standards, the bill seeks to harmonize state regulations with national professional benchmarks, potentially affecting licensure, inspections, and enforcement related to compounding pharmacies.
  • Enforcement and oversight: The bill would assign enforcement responsibilities and may specify penalties or corrective actions for noncompliance with the adopted standards or approved exemptions.

Who would be affected

  • Compounding pharmacies and pharmacists: The primary actors impacted, as they would need to comply with USP-based requirements in routine compounding and apply for any authorized exemptions.
  • Patients and healthcare providers: Beneficiaries of higher consistency and quality in compounded medications; exemptions could affect access in specific scenarios.
  • State regulatory agencies: Agencies responsible for pharmacy licensure, inspections, and enforcement would implement and monitor adherence to the new standards and exemptions.

Procedural and timeline aspects

  • Introduction and referral: Introduced February 24, 2026; referred to the House Committee on Health and Human Services (Feb 6, 2026) and subsequently to the Senate Committee on Public Health and Welfare (Feb 25, 2026).
  • Committee actions: Progressed through House committees, including House Health and Human Services and a Committee of the Whole, with a House committee report recommending passage (Feb 17, 2026) and the Committee of the Whole order (Feb 18, 2026).
  • Senate status: Died in Senate Committee on Public Health and Welfare as of April 10, 2026, ending likely further advancement in the 2025-2026 session without passage.
  • Effective date and exemptions: The specific effective date for the standards and the process for exemptions would be detailed in the bill text; as reported, these would typically become effective upon enactment or a stated compliance period unless otherwise exempted.

Potential impact and considerations

  • Quality and standards: Adoption of USP standards could raise consistency and quality in compounded medications across Kansas.
  • Access considerations: Exemption provisions may allow flexibility in unique clinical situations but could also create variability depending on how exemptions are granted.
  • Implementation workload: Pharmacies may need to update standard operating procedures, quality control documentation, and training to align with USP standards.
  • Regulatory clarity: Clear definitions of what constitutes an exemption, who can grant it, and under what conditions are critical to prevent ambiguity in enforcement.

Note: The bill ultimately died in the Senate Committee, meaning it did not become law in the 2025-2026 session. If reintroduced, future iterations might address the Senate concerns or adjust exemption criteria and implementation timelines.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.